Biotech Insights & Expert Advice

At Ansa, we’re fortunate to have not one but three scientific founders, all of whom are still with the company and helping to improve our synthesis technology with new innovations on a regular basis.

At Ansa, we’re on a mission to end the headaches of ordering synthetic DNA and give researchers what they really want: reliable DNA, on time, exactly as ordered.

Most companies struggle to reliably produce large, complex sequences, forcing scientists to settle for simpler, shorter fragments that can compromise their research.

With Ansa's technology, researchers will now be able to more fully explore the complex relationship between coding sequence and function than has been possible in the past.

Life science research has been limited for decades — not because of scientists’ ambitions but because of outdated technology.

By delivering multiplexed CRISPR arrays and the newly characterized IS110 systems, Ansa enables editing multiple loci in genomes at once, dramatically increasing the rate of learning how multiple edits interact with one another.

In 2018, Ansa co-founders Dan-Lin Arlow, “a computer kid” growing up, and Sebastian Palluk, an athlete turned biologist, published “De novo DNA synthesis using polymerase-nucleotide conjugates” in Nature Biotechnology.

For scientists, getting access to complex DNA has historically been challenging. Scientists themselves, our founders experienced the frustrations first-hand, which is why they were driven to develop a more effective and efficient solution. In doing so, we are excited to work with companies like Touchlight…

Six years into our journey at Ansa Biotechnologies, we can proudly say that we have succeeded at building an enzymatic DNA synthesis technique superior to the prior gold standard, the phosphoramidite method.